. . . . . "Open PHACTS (Open Pharmacological Concept Triplestone) is public-private partnership between academia, publishers, enterprises, pharmaceutical companies and other organisations working to enable better, cheaper and faster drug discovery. It has been funded under a European grant from the Innovative Medicines Initiative . A total of 27 partners are currently involved including:"@en . . . "Semantic interoperability for drug discovery"@en . . . . . "Deliver and sustain an Open Pharmacological Space"@en . . "2011"^^ . "Open PHACTS (Open Pharmacological Concept Triplestone) is public-private partnership between academia, publishers, enterprises, pharmaceutical companies and other organisations working to enable better, cheaper and faster drug discovery. It has been funded under a European grant from the Innovative Medicines Initiative . A total of 27 partners are currently involved including: \n* Academia: Maastricht University, the University of Santiago de Compostela, The University of Vienna the University of Manchester, the University of Bonn, the Swiss Institute of Bioinformatics, the European Bioinformatics Institute, the Vrije Universiteit of Amsterdam, the Technical University of Denmark and the University of Hamburg \n* Pharmaceutical companies: Pfizer, Merck KGaA, Eli Lilly and Company, Novartis, GlaxoSmithKline and AstraZeneca \n* enterprises: ChemSpider \n* publishers: Royal Society of Chemistry The Open Pharmacological Space created by the consortium is intended to facilitate improvements in drug discovery and to support open innovation and in-house non-public drug discovery research. Resources from the project are available on GitHub"@en . . "frameless"@en . "Open PHACTS"@en . "Open PHACTS"@en .